StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Ribociclib

HCID 44631912
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
1211441-98-3
Standard-SMILES
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1
InChIKey
RHXHGRAEPCAFML-UHFFFAOYSA-N
Summenformel
C23H30N8O
Durchschnittliche Molmasse
434,5 g/mol
Monoisotopische Masse
434,25425761

Überblick

Ribociclib is a member of piperazines and a member of pyridines.

Namen und Bezeichner

Bevorzugter Name
Ribociclib
IUPAC
7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-yl-2-pyridinyl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
Englischer Name
Ribociclib
Summenformel
C23H30N8O
Molmasse
434.54

Namen und Synonyme

Ribociclib1211441-98-3LEE011LEE-0117-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamideTK8ERE8P56LEE011A7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamideLEE-011ADTXSID201021027ribociclibum7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo(2,3-d)pyrimidine-6-carboxamide
Weitere Namen anzeigen
7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamideLEE01LEE11CS-1001Kisqali.LEE011, >=98%Ribociclib-d8Ribociclib base
RefChem:55976L01XE42DTXCID701506068807-111-0Ribociclib (LEE011)LEE 011KisqaliRibociclib [INN]

Eigenschaften

Berechnete Struktureigenschaften

XLogP
2,2
Polarare Oberfläche (TPSA)
91,2 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
7
Frei drehbare Bindungen
5
Schwere Atome
32
Formalladung
0
Komplexität
635

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

Physikochemische Eigenschaften

Siedepunkt
730.8 · 730.8±70.0 °C(Predicted)
Dichte
1.39 · 1.39±0.1 g/cm3(Predicted)
Dampfdruck
0 · 0-0Pa at 20-25℃
storage temp.
-20 °C · -20°C
Löslichkeit
Soluble in DMSO (up to 10 mg/ml)
pka
8.67 · 8.67±0.10(Predicted)
Aggregatzustand
solid
Farbe
Off-white
Stabilität
1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 14.3% (1 of 7) of reports.

Danger

H360 (14.3%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P260, P273, P280, P318, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 7 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationREACH registered substance: 7-Cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (EC: 807-111-0)
Hazard Classes and CategoriesRepr. 1B (14.3%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

In the large clinical trials, adverse events were common and led to dose reductions in 45% of patients and discontinuation in 7%. In preregistration clinical trials, ALT elevations occurred in 46% of ribociclib vs 36% of control subjects and elevations above 5 times the ULN in 10% vs 1%. In one study, 1% of recipients developed clinically apparent liver injury with jaundice, but all recovered. The liver injury arose after 3 to 5 cycles and presented with asymptomatic elevations in serum ALT followed by symptoms and jaundice. Immunoallergic and autoimmune features were not present, although liver histology sometimes showed autoimmune hepatitis-like features. Recovery was slow (3 to 5 months), but ultimately complete. Restarting ribociclib resulted in more rapid and severe recurrence. Thus, experience with ribociclib is limited, but it appears to be capable of causing significant liver injury.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein Binding_In vitro_, ribociclib is 70% protein-bound independent of concentration.
Pharmacodynamics · 1 Eintrag

Ribociclib causes concentration-dependent changes in QTcF interval. It should be used with caution in patients undergoing treatment with other QTc-prolonging agents, or in patients pre-disposed to the development of Torsades de Pointes (TdP) (e.g. those with long QT syndrome, LQTS).

Mechanism of Action · 1 Eintrag

Ribociclib is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and are downstream of signaling pathways which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb). Ribociclib has been shown _in vitro_ to decrease pRb phosphorylation, resulting in arrest in the G1 phase of the cell cycle and reduced proliferation in breast cancer-derived models. The inhibition of pRb phosphorylation is correlated with a decrease in the volume of tumor cells.

Biological Half-Life · 1 Eintrag

At steady-state in patients with advanced cancer, the mean plasma effective half-life of ribociclib was 32 hours. In healthy adults receiving the 600 mg dose, the mean apparent plasma terminal half-life of ribociclib ranged from 29.7 to 54.7 hours and mean apparent oral clearance of ribociclib ranged from 39.9 to 77.5 L/h.

Metabolism/Metabolites · 1 Eintrag

Ribociclib undergoes extensive hepatic metabolism, primarily via oxidative reactions mediated by CYP3A4. Major circulating metabolites following oral administration include metabolite M13 (CCI284, N-hydroxylation), M4 (LEQ803, N-demethylation), and M1 (secondary glucuronide), each representing an estimated 9%, 9%, and 8% of total radioactivity, and 22%, 20%, and 18% of ribociclib exposure. Parent drug is the major circulating entity in plasma, accounting for 44% of total exposure.

Zugehörige Reaktionen

116
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 113073
HRID 113073als Edukt
Reaktionsgleichung von HRID 156065
HRID 156065als Edukt
Reaktionsgleichung von HRID 159473
HRID 159473als Edukt
Reaktionsgleichung von HRID 177171
HRID 177171als Edukt
Reaktionsgleichung von HRID 186070
HRID 186070als Edukt
Reaktionsgleichung von HRID 311519
HRID 311519als Edukt
Reaktionsgleichung von HRID 663560
HRID 663560als Edukt
Reaktionsgleichung von HRID 686178
HRID 686178als Edukt
ZurückSeite 1 von 15

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
1211441-98-3、1374639-75-4
PubChem CID
44631912
DTXSID
DTXSID201021027
ChEMBL
CHEMBL3545110
ChEBI
CHEBI:230905
UNII
TK8ERE8P56
EC Number
807-111-0
Nikkaji
J3.462.341D
InChIKey
RHXHGRAEPCAFML-UHFFFAOYSA-N
SMILES
C1(NC2=NC=C(N3CCNCC3)C=C2)=NC=C2C=C(C(N(C)C)=O)N(C3CCCC3)C2=N1
LogP
-0.8 · -0.8-2.3 at 20℃ and pH4-11
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302
FDA Pharmacological Classification · 6 Einträge

TK8ERE8P56

RIBOCICLIB

Established Pharmacologic Class [EPC] - Kinase Inhibitor

Mechanisms of Action [MoA] - Kinase Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 3A Inhibitors

Ribociclib is a Kinase Inhibitor. The mechanism of action of ribociclib is as a Kinase Inhibitor and Cytochrome P450 3A Inhibitor.

Absorption, Distribution and Excretion · 4 Einträge

The mean absolute bioavailability of ribociclib after a single oral dose of 600 mg was 65.8%. Following repeated 600 mg once daily administration, steady-state was generally achieved after 8 days and the mean steady-state Cmax and AUC were 1820 ng/mL and 23800 ng*h/mL, respectively. The Tmax of ribociclib at steady-state generally occurs between 1 and 4 hours following administration.

Unchanged parent drug accounts for only 17% and 12% of the administered dose excreted in feces and urine, respectively. Metabolite M4 (LEQ803) represented approximately 14% and 4% of the administered dose in feces and urine, respectively.

At steady-state, the apparent volume of distribution of ribociclib was 1090 L.

At steady-state in patients with advanced cancer administered receiving the 600 mg dose, the mean apparent oral clearance of ribociclib was 25.5 L/h. At steady-state in patients with early breast cancer administered receiving the 400 mg dose, the mean apparent oral clearance of ribociclib was 38.4 L/h.

Anwendungen · 2 Einträge

BeschreibungLEE011 is a cyclin-dependent kinase (CDK) inhibitor that targets cyclin D1/CDK4 and cyclin D3/CDK6 at nanomolar concentrations. It inhibits retinoblastoma protein phosphorylation, which prevents CDK-mediated G1-S phase transition, arresting the cell cycle in the G1 phase, suppressing DNA synthesis, and inhibiting cancer cell growth. LEE011 has been shown to reduce proliferation in 12 of 17 human neuroblastoma-derived cell lines by inducing cytostasis (mean IC50 = 306 nM in sensitive lines).

VerwendenLEE 011 can be used in biological study of kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer.